Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Mol Immunol. 2015 Feb;63(2):479–488. doi: 10.1016/j.molimm.2014.10.005

Fig. 3. Treatment in vivo with mAb 4B2 does not induce B cell elimination.

Fig. 3

(A) Mice were injected with increasing (250, 750 or 1000 μg per mouse) doses of mAb 4B2, control IgG1, or with PBS alone. After 24 hours splenocytes were studied by flow cytometry to quantitative the percentage of CD4+ cells (filled bar), B220+ cells (cross hatched), and CD8+ cells (horizontal stripes). (B) Mice were injected similarly as in (A) at day 0. One day later mice were immunized by intra-dermal injection with 100 μg of bovine CII. Seven days after immunization splenocytes were assayed for CD4, CD8 and B220+ cell percentages. As in (A), no B cell elimination was detected. (C) Injection with mAb 4B2 diminishes the relative marginal zone (MZ) B cell sub-population. Mice were injected as in (B) with mAb 4B2 or control IgG1, or with PBS, followed by CII intradermal injection. Seven days after immunization spleens were analyzed for splenic B cell subpopulations. B220+ cells were analyzed for follicular (unfilled bar), transitional (striped), immature (filled gray), and MZ cells (filled black). A significant 50–70% reduction in the MZ B cell subpopulation was observed in mice pre-injected with mAb 4B2.